Exchange Traded Concepts LLC Sells 14,999 Shares of Guardant Health, Inc. (NASDAQ:GH)

Exchange Traded Concepts LLC lessened its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 36.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 26,010 shares of the company's stock after selling 14,999 shares during the period. Exchange Traded Concepts LLC's holdings in Guardant Health were worth $795,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GH. JNBA Financial Advisors purchased a new stake in shares of Guardant Health in the third quarter valued at $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Guardant Health in the 3rd quarter valued at about $34,000. Quarry LP acquired a new position in shares of Guardant Health in the 2nd quarter valued at about $44,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Guardant Health in the 2nd quarter valued at about $71,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Guardant Health by 168.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,434 shares of the company's stock valued at $79,000 after purchasing an additional 2,153 shares during the period. 92.60% of the stock is owned by institutional investors.

Insider Activity at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares of the company's stock, valued at $228,675.20. This trade represents a 27.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Musa Tariq sold 2,320 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares of the company's stock, valued at approximately $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,548 shares of company stock valued at $179,782. 5.50% of the stock is owned by insiders.

Guardant Health Price Performance

Shares of GH stock traded up $2.15 on Thursday, reaching $49.80. 881,791 shares of the stock were exchanged, compared to its average volume of 2,481,090. Guardant Health, Inc. has a one year low of $15.81 and a one year high of $50.78. The stock has a market cap of $6.15 billion, a PE ratio of -11.73 and a beta of 1.28. The stock has a 50 day moving average price of $36.31 and a 200 day moving average price of $29.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The firm had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same quarter in the prior year, the company earned ($0.73) EPS. Guardant Health's quarterly revenue was up 33.9% on a year-over-year basis. On average, research analysts expect that Guardant Health, Inc. will post -3.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on GH shares. The Goldman Sachs Group lifted their price target on Guardant Health from $36.00 to $49.00 and gave the company a "buy" rating in a report on Tuesday. JPMorgan Chase & Co. increased their price objective on Guardant Health from $48.00 to $50.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Guggenheim reissued a "buy" rating on shares of Guardant Health in a report on Wednesday, January 22nd. Sanford C. Bernstein decreased their price objective on shares of Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a report on Wednesday, October 30th. Finally, Barclays started coverage on shares of Guardant Health in a report on Thursday, January 23rd. They set an "overweight" rating and a $60.00 price objective for the company. Sixteen analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $42.63.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.